期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
CD10基因表达与胰腺神经内分泌癌诊断 被引量:1
1
作者 陈俊鹏 何贾红 林春平 《中国医药科学》 2011年第10期64-65,共2页
目的为研究CD10与胰腺神经内分泌癌的关联性,探讨CD10在胰腺神经内分泌癌中的表达情况。方法采用免疫组织化学方法,检测28例胰腺神经内分泌癌和10例正常胰腺组织中CD10的表达,分析CD10在胰腺神经内分泌癌中的表达情况。结果胰腺神经内... 目的为研究CD10与胰腺神经内分泌癌的关联性,探讨CD10在胰腺神经内分泌癌中的表达情况。方法采用免疫组织化学方法,检测28例胰腺神经内分泌癌和10例正常胰腺组织中CD10的表达,分析CD10在胰腺神经内分泌癌中的表达情况。结果胰腺神经内分泌癌中CD10的表达率为82.13%,明显高于正常对照阴性组(P<0.05)。结论胰腺神经内分泌癌可能存在着CD10的高表达,这种高表达也许能够成为胰腺神经内分泌癌的诊断指标之一。 展开更多
关键词 胰腺神经内分泌癌 CD10 免疫组织化学
在线阅读 下载PDF
CT增强鉴别胰腺神经内分泌癌与胰腺癌 被引量:8
2
作者 岳亚丽 刘绍伟 +3 位作者 刘永康 任帅 王中兰 王中秋 《医学影像学杂志》 2018年第2期242-245,共4页
目的分析PNEC与PDAC的临床及影像学特点,寻找具有鉴别价值的临床或影像学征象,以期提高术前诊断准确率。方法回顾性分析经病理证实的11例PNEC与20例PDAC患者的临床及影像学资料,观察病变位置、大小、形态、边界,测量病灶、周围正常胰腺... 目的分析PNEC与PDAC的临床及影像学特点,寻找具有鉴别价值的临床或影像学征象,以期提高术前诊断准确率。方法回顾性分析经病理证实的11例PNEC与20例PDAC患者的临床及影像学资料,观察病变位置、大小、形态、边界,测量病灶、周围正常胰腺组织平扫及增强扫描各期CT值,计算并采用两样本T检验方法比较两组相对密度指数;另外观察分析胰管、胆管扩张情况及远端胰腺萎缩、邻近组织受侵或远处转移等征象。结果 PNEC组病灶边界相对PDAC更为清晰;PNEC病灶于各期CT值均高于PDAC,且二者动脉期及静脉期相对密度指数有明显的差异,但平扫及延迟期病灶相对密度指数接近,不易区分两组病灶;PDAC组出现胰腺萎缩的概率高于PNEC,差异有统计学意义;胰、胆管扩张、淋巴结转移、局部侵犯或远处转移等征象对于区分两者无显著意义。结论 PNEC与胰腺癌可出现不同程度的影像重叠征象,容易误诊,但PNEC相对于PDAC边界较清,动脉期及静脉期相对密度指数高于PDAC,以及较少出现胰腺萎缩等征象有助于鉴别诊断。 展开更多
关键词 胰腺神经内分泌癌 胰腺导管腺 体层摄影术 X线计算机
在线阅读 下载PDF
Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?
3
作者 Liang Wang Gang Li +4 位作者 Yun-tao Bing Mao-lin Tian Hangyan Wang Chunhui Yuan Dianrong Xiu 《Chinese Medical Sciences Journal》 CAS CSCD 2021年第4期284-294,共11页
Objective To investigate the impact of prior non-pancreatic cancer on the survival outcomes of patients with localized pancreatic neuroendocrine tumors(Pan NETs).Methods We reviewed the Surveillance,Epidemiology,and E... Objective To investigate the impact of prior non-pancreatic cancer on the survival outcomes of patients with localized pancreatic neuroendocrine tumors(Pan NETs).Methods We reviewed the Surveillance,Epidemiology,and End Results database and selected patients with localized Pan NETs diagnosed between 1973 and 2015.We divided the patients into two groups according to the presence or absence of prior non-pancreatic malignancy.Before and after propensity score matching,we compared the clinicopathological characteristics and studied the overall survival and cancer-specific survival.Results A total of 357(12.9%)of 2778 patients with localized Pan NETs had prior cancer.A total of 1211 cases with only a localized Pan NET and 133 cases with a localized Pan NET and prior cancer had complete data and met the inclusion criteria of the current study.Patients with prior cancer were associated with advanced age(>65 years,57.9%prior cancer vs.31.0%no prior cancer,P<0.001),later year of diagnosis(87.2%vs.80.2%,P=0.049),a higher proportion of poorly differentiated/undifferentiated grade tumors(4.5%vs.1.5%,P=0.025),and a higher proportion of no primary site surgery(19.5%vs.10.4%,P=0.003).Prostate(29.32%),breast(18.05%),other genitourinary and retroperitoneal(16.54%),and gastrointestinal(12.78%)cancers were the most common prior cancer types.Most of the prior cancers(95.49%)were localized and regional,and only 4.51%of the prior cancers were distant.Patients with interval periods between the prior cancer and Pan NET of≤36 months,36-60 months,60-120 months,and>120 months accounted for 33.08%,13.53%,24.06%,and 29.32%of all cases with prior cancers,respectively.Univariate and multivariate Cox proportional hazards analyses were performed.The presence/absence of prior cancers did not impact survival outcomes of patients with localized Pan NETs before and after propensity score matching(PSM).Further subgroups analysis showed that,patients with localized Pan NETs and prior distant cancer had worse cancer-specific survival than patients with prior local/regional cancer or patients without prior cancer(P<0.001).No significant differences in cancerspecific survival were observed in terms of the different sites of the prior cancers and the different interval periods of prior cancers and Pan NETs(P<0.05).Conclusions Patients with localized Pan NETs and a history of prior cancer had survival outcomes that were comparable to those of patients with no history of prior cancer.Patients with localized Pan NETs and prior cancer could be candidates for clinical trials if they satisfy all other conditions;aggressive and potentially curative therapies should be offered to these patients. 展开更多
关键词 pancreatic neuroendocrine tumor prior cancer propensity score matching
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部